Tankyrase 1 has received attention as a promising target for anti-cancer therapies due to its upregulated expression in various cancer types. Its crucial role in PARsylation leads to the degradation of tumor suppressors (e.g. Axin, TRF1, and PTEN) through the ubiquitin-proteasome pathway, highlighting its significance in oncogenic processes. The urgency to discover novel tankyrase 1 inhibitors …